Company / Capital Expenditures
4D Molecular Therapeutics, Inc. Capital Expenditures History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$3.8M
FY2025
5-year range
$1.0M / $11.5M
FY2021-FY2025
Trend
+36.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has fluctuated over the past 6 years, ranging from $1M in FY2021 to $12M in FY2023.
Based on SEC 10-K filings.
$4M in FY2025 with a 5-year CAGR of +3.4%.
Declined from $12M to $4M over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -25.4%
- 5-Year CAGR
- +3.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +3.4%, indicating consistent growth.
- In FY2025, capital expenditures increased 36.6% year-over-year.
- Peak capital expenditures was recorded in FY2023.
- Lowest capital expenditures in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.26 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.8M | +36.6% |
| FY2024 | $2.8M | -76.0% |
| FY2023 | $11.5M | +26.6% |
| FY2022 | $9.1M | +811.0% |
| FY2021 | $1.0M | -68.8% |
| FY2020 | $3.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026